Pancreatic cancer is on the rise. Deaths caused by pancreatic cancer surpassed breast cancer a few years ago, and pancreatic cancer remains on track to overtake colorectal cancer to move to the second leading cause of cancer-related deaths in the United States this year.* The number of cases of pancreatic cancer is also increasing globally.
Although advances in cancer treatments continue to grow, there is still a great need for new therapies.
Hilar Cholangiocarcinoma (HCCA):
Hilar Cholangiocarcinoma (HCCA), also known as extra-hepatic (outside-the-liver) bile duct cancer, can affect any of the ducts (tubes) that connect the liver, gallbladder, and small intestine. According to Cancer.net, the 5-year survival rate ranges between 2 and 24%, depending on when the cancer is discovered.
Due to toxicities of the current standard of care, a practice standard of care has not been established for HCCA.
Confidential Application Development:
RenovoRx is actively planning for development of additional RenovoGem (intra-arterial gemcitabine in combination with our proprietary RenovoCath delivery system) applications to meet unmet needs in cancer treatment.
* Gaduputi, V, Rawla, Prashanth, et al. “Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors.” World J Oncol. 2019 Feb; 10(1): 10–27.